AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces
Executive Summary
Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.
You may also be interested in...
AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
Roche/Abbvie's Venclexta Outshines Agios IDH Inhibition In AML At ASH
Clinicians weigh in on updated data presented at ASH in frontline acute myeloid leukemia, but caution that it is difficult to compare across clinical trials.
Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days
Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.